China’s National Medical Products Administration approved Suzhou Alphamab’s anbenitamab (KN-026), a HER2 bispecific antibody, for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received at least one trastuzumab-containing regimen. NMPA granted the therapy priority review, signaling a faster pathway for a continuing push toward bispecific options in HER2-driven solid tumors.